Table 1 Progression of thyroid hormone levels, ejection fraction and cardiac biomarkers after substitution therapy with levothyroxine had been initiated. Reference ranges are reported with units of measurement
From: Second degree AV block and severely impaired contractility in cardiac myxedema: a case report
Days after admission | 0 | 0 | 1 | 2 | 5 | 9 | 28 | 83 | 120 |
|---|---|---|---|---|---|---|---|---|---|
(external) | |||||||||
Concentrations of thyroid hormones | |||||||||
TSH | >100 | 108.34 | >100 | >100 | >100 | 78.65 | 30.31 | 13.86 | 7.61 |
(0.35–3.5 mIU/L) | |||||||||
Free T3 | 2.4 | 2.7 | 2.7 | 3.1 | 4.5 | 4.2 | 4.2 | 4.4 | |
(3.5–6.3 pmol/L) | |||||||||
Free T4 | <3.9 | <3.9 | <3.9 | 6.44 | 9.0 | 12.87 | 12.87 | 16.73 | |
(8–18 pmol/L) | |||||||||
Echocardiography and MRT | |||||||||
EF | 25 | 38 | 60 | 55 | 58 | ||||
(55–70 %) | |||||||||
Cardiac output | 3.2 | 6.0 | |||||||
(2.8–8.8 L/min) | |||||||||
Concentrations of cardiac biomarkers | |||||||||
CK | 437 | 311 | 223 | 154 | |||||
(0–172 U/L) | |||||||||
CK-MB | 34 | 24 | |||||||
(<24 U/l) | |||||||||
Troponin I | <0.04 | ||||||||
(0–0,04 μg/l) | |||||||||